1832 Asset Management
KRYS icon

1832 Asset Management’s Krystal Biotech KRYS Stock Holding History

1832 Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9M Buy
99,300
+56,700
+133% +$16.9M 0.02% 278
2026
Q1 		$11M Buy
42,600
+25,000
+142% +$6.65M 0.01% 360
2025
Q4 		$4.34M Buy
+17,600
New +$3.7M ﹤0.01% 448
2025
Q2 		– Sell
-136,000
Closed -$24.5M – 718
2025
Q1 		$24.5M Buy
+136,000
New +$22.9M 0.02% 270

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

1832 Asset Management's KRYS Position: Q2 2026 in Review

1832 Asset Management increased its Krystal Biotech (KRYS) stake by 133% in Q2 2026, buying an estimated $16.9M and bringing the position to 99,300 shares worth $36.9M. The position accounts for 0.02% of the portfolio, ranked #278.

1832 Asset Management first reported a position in KRYS in Q1 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • 1832 Asset Management held 99,300 shares of Krystal Biotech worth $36.9M as of Q2 2026.
  • 1832 Asset Management bought 56,700 Krystal Biotech shares in Q2 2026, an estimated $16.9M.
  • Krystal Biotech made up 0.02% of 1832 Asset Management's portfolio in Q2 2026, its #278 holding.
  • 1832 Asset Management first reported a position in Krystal Biotech in Q1 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on 1832 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.